1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ivermectin / Pyrantel Formulation

Manufacturer or supplier’s details
Company : MSD
Address : Briahnager - Off Pune Nagar Road
          Wagholi - Pune - India  412 207
Telephone : 908-740-4000
Emergency telephone number : 1-908-423-6000
E-mail address : EHSDATASETWARD@msd.com
Telefax : 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989
Classification
Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification
Short-term (acute) aquatic hazard : Category 1
Long-term (chronic) aquatic hazard : Category 1

GHS label elements
Hazard pictograms : 

Signal word : Warning
Hazard statements : H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements : Prevention:
P273 Avoid release to the environment.
Response:
P391 Collect spillage.
Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Additional Labelling
The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 8.6 %

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)</td>
<td>22204-24-6</td>
<td>&gt;= 5 - &lt; 10</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>7647-14-5</td>
<td>&gt;= 1 - &lt; 5</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>&gt;= 0.0025 - &lt; 0.025</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
In case of skin contact : Wash with water and soap.
In case of eye contact : If in eyes, rinse well with water.
If swallowed : If swallowed, DO NOT induce vomiting.
Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders : No special precautions are necessary for first aid responders.
Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical
Unsuitable extinguishing media: None known.

Specific hazards during firefighting:
Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
Carbon oxides
Nitrogen oxides (NOx)
Sulphur oxides
Metal oxides
Chlorine compounds

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters:
Wear self-contained breathing apparatus for firefighting if necessary.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions:
Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures:
Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding.
Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling:
- Do not breathe dust.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labelled containers.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)</td>
<td>22204-24-6</td>
<td>TWA</td>
<td>250 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>TWA</td>
<td>0.05 mg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: Skin
- Wipe limit 0.5 mg/100 cm²  Internal

Engineering measures:
- All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
- Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
- Minimize open handling.

Personal protective equipment

Respiratory protection:
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection

Material: Chemical-resistant gloves

Remarks: Consider double gloving.

Eye protection:
- Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: powder
Colour: brown
Odour: No data available
Odour Threshold: No data available
pH: 4 - 6 (20 °C) (as aqueous solution)
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: Not applicable
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
SAFETY DATA SHEET

Ivermectin / Pyrantel Formulation

Vapour pressure : Not applicable
Relative vapour density : Not applicable
Relative density : No data available
Density : No data available
Solubility(ies)
  Water solubility : No data available
Partition coefficient: n-octanol/water : Not applicable
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, kinematic : Not applicable
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions
  : May form explosive dust-air mixture during processing, handling or other means.
  Can react with strong oxidizing agents.
Conditions to avoid : Heat, flames and sparks.
  Avoid dust formation.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
  : Inhalation
  Skin contact
  Ingestion
  Eye contact

Acute toxicity
  Not classified based on available information.

Product:
  Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
  Method: Calculation method
Components:

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Acute oral toxicity: LD50 (Rat): > 24,000 mg/kg
LD50 (Mouse): > 24,000 mg/kg
LD50 (Dog): 2,000 mg/kg

Sodium chloride:

Acute oral toxicity: LD50 (Rat): 3,550 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 42 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): > 5,000 mg/kg

Ivermectin:

Acute oral toxicity: LD50 (Rat): 50 mg/kg
LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity: LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Sodium chloride:
Species: Rabbit
Result: No skin irritation

Ivermectin:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.
Components:

Sodium chloride:
Species: Rabbit
Result: No eye irritation

Ivermectin:
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Sodium chloride:
Test Type: Local lymph node assay (LLNA)
Exposure routes: Skin contact
Species: Mouse
Result: negative

Ivermectin:
Exposure routes: Dermal
Species: Humans
Result: Does not cause skin sensitisation.

Germ cell mutagenicity
Not classified based on available information.

Components:

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Sodium chloride:
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Saccharomyces cerevisiae, gene mutation assay (in vitro)
Result: positive

Test Type: DNA damage and repair, unscheduled DNA syn-
thesis in mammalian cells (in vitro)
Result: positive

Test Type: Chromosome aberration test in vitro
Result: positive

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo: Test Type: In vivo micronucleus test
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Intraperitoneal injection
Result: positive

Germ cell mutagenicity - Assessment: Weight of evidence does not support classification as a germ cell mutagen.

Ivermectin:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts
Result: negative

Test Type: Mouse Lymphoma
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Sodium chloride:
Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

Ivermectin:
Species: Rat
Application Route: Oral
NOAEL: 1.5 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials
Species: Mouse
Application Route: Oral
NOAEL: 2.0 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

Reproductive toxicity
Not classified based on available information.

Components:

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Effects on foetal development:
- Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Oral
  - Developmental Toxicity: NOAEL: 3,000 mg/kg body weight
  - Result: No effects on fertility and early embryonic development were detected.

  - Test Type: Embryo-foetal development
    - Species: Rabbit
    - Application Route: Oral
    - Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
    - Result: No effects on fertility and early embryonic development were detected.

Ivermectin:

Effects on fertility:
- Test Type: Fertility
  - Species: Rat
  - Application Route: Oral
  - Fertility: NOAEL: 0.6 mg/kg body weight
  - Result: Animal testing did not show any effects on fertility.

Effects on foetal development:
- Test Type: Development
  - Species: Mouse
  - Application Route: Oral
  - Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
  - Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

  - Test Type: Development
    - Species: Rat
    - Application Route: Oral
    - Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
    - Result: Embryotoxic effects and adverse effects on the offspring were detected.
    - Remarks: The mechanism or mode of action may not be relevant in humans.

  - Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

**STOT - single exposure**
Not classified based on available information.

**Components:**

**Ivermectin:**
Target Organs: Central nervous system
Assessment: Causes damage to organs.

**STOT - repeated exposure**
Not classified based on available information.

**Components:**

**Ivermectin:**
Target Organs: Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>30 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>3 d</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>600 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>19 d</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>600 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>600 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 d</td>
</tr>
</tbody>
</table>
Remarks : No significant adverse effects were reported

Sodium chloride:
Species : Rat
LOAEL : 2,533 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

Ivermectin:
Species : Dog
NOAEL : 0.5 mg/kg
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Central nervous system
Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey
NOAEL : 1.2 mg/kg
Application Route : Oral
Exposure time : 2 Weeks
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 0.4 mg/kg
LOAEL : 0.8 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : spleen, Bone marrow, Kidney

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea, Headache, Dizziness, Fever

Ivermectin:
Skin contact : Remarks: Can be absorbed through skin.
Eye contact : Remarks: May irritate eyes.
Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination
12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded
Chronic aquatic toxicity : Toxic effects cannot be excluded

Sodium chloride:

Toxicity to fish : EC50 (Daphnia magna (Water flea)): 4,136 mg/l
Exposure time: 10 d

Toxicity to fish (Chronic toxicity) : NOEC: 314 mg/l
Exposure time: 21 d
Species: Daphnia pulex (Water flea)

Toxicity to algae/aquatic plants : EC50: > 2,000 mg/l
Exposure time: 96 h

Toxicity to microorganisms : EC10: > 1,000 mg/l

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity) : 10,000

M-Factor (Chronic aquatic toxicity) : 10,000

Persistence and degradability

Components:

Ivermectin:
Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50%
Exposure time: 240 days

Bioaccumulative potential

Components:

Ivermectin:
Bioaccumulation : Bioconcentration factor (BCF): 74
Partition coefficient: n-octanol/water : log Pow: 3.22

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)

Class : 9
Packing group : III
Labels : 9

IATA-DGR
SAFETY DATA SHEET

Ivermectin / Pyrantel Formulation

Version 2.14  Revision Date: 19.05.2020  SDS Number: 52863-00017  Date of last issue: 23.03.2020

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Ivermectin)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)
Class : 9
Subsidiary risk : ENVIRONM.
Packing group : III
Labels : 9 (ENVIRONM.)
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to IMO instruments
Not applicable for product as supplied.

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

16. OTHER INFORMATION

Further information

Date format : dd.mm.yyyy
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IN / EN